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Abstract. Haiti is targeting malaria elimination by 2025. The Grand’Anse department in southwestern Haiti experi-
ences one-third to half of all nationally reported Plasmodium falciparum cases. Although there are historical reports
of Plasmodium vivax and Plasmodium malariae, today, non-falciparum infections would remain undetected because of
extensive use of falciparum-specific histidine-rich protein 2 (HRP2) rapid diagnostic tests (RDT) at health facilities. A
recent case–control study was conducted in Grand’Anse to identify risk factors for P. falciparum infection using HRP2-
based RDTs (n = 1,107). Post hoc multiplex Plasmodium antigenemia and antibody (IgG) detection by multiplex bead
assay revealed oneblood sample positive for pan-Plasmodium aldolase, negative forP. falciparumHRP2, andpositive for
IgG antibodies toP.malariae. Based on this finding, we selected 52 samples with possibleP.malariae infection using IgG
andantigenemiadataandconfirmed infection statusbyspecies-specificPCR.WeconfirmedoneP.malariae infection in a
6-month-old infant without travel history. Congenital P. malariae could not be excluded. However, our finding—in
combinationwith historical reports ofP.malariae—warrants further investigation into the presence and possible extent of
non-falciparum malaria in Haiti. Furthermore, we showed the use of multiplex Plasmodium antigen and IgG detection in
selecting samples of interest for subsequent PCR analysis, thereby reducing costs as opposed to testing all available
samples by PCR. This is of specific use in low-transmission or eliminating settings where infections are rare.
INTRODUCTION
Although historically considered benign, the severity of
non-falciparum malaria has now been recognized.1 Despite
the substantial geographical distribution of Plasmodium
malariae, global and regional estimates of its prevalence
are largely unknown or almost certainly underestimated.1–5
Plasmodium malariae has been associated with anemia,
hospitalization, splenomegaly, kidney damage (specifically
in children6), and death.7,8 There are sporadic reports of
congenital P. malariae causing fever and anemia in newborn
infants.9,10
In some cases, P. malariae can cause prolonged low-level
parasitemia which can remain undetected for years.11 These
silent infections can threaten malaria elimination efforts in
areas where Plasmodium falciparum is the dominant spe-
cies.12 Surveillance for non-falciparum malaria should there-
forenot beoverlooked in acountry attempting to reachmalaria
elimination.However, affordablemethods for identifying these
infections in routine surveillance are currently not available.
PCR remains impractical at large scale owing to costs, pro-
cessing time, and the lack of appropriate laboratories in many
endemic settings. Multiplex bead assays (MBAs) can be used
to rapidly collect antibody and antigen data at small scale,
thereby selecting samples of interest for confirmation by
PCR.13,14 Because of the limited incremental costs of adding
non-falciparum and/or pan-Plasmodium targets to a
P. falciparum antigen and antibody detection panel on an
MBA, this is a highly cost-effective approach to identify the
presence of possible non-falciparum infections.
Today, malaria transmission in Haiti is primarily due to P.
falciparum, although there are historical reports of P. malariae
and Plasmodium vivax.15,16 Evidence for P. malariae was
found in Haitian refugees arriving in Jamaica in 2004.17 Haiti
and the Dominican Republic, sharing the island of Hispaniola,
aim to eliminate malaria by 2025 (www.malariazeroalliance.org).
Althoughmalaria elimination activities targetP. falciparum and
P. vivax, the elimination goal includes allPlasmodium species.
As P. malariae has caused outbreaks decades after apparent
successful elimination in other regional settings (i.e., Granada
and Trinidad18,19), it is important to knowwhether this parasite
is endemic. Following the devastating 2010 earthquake in
Haiti, rapid diagnostic tests (RDTs) were deployed for malaria
diagnosis to supplement microscopy, which was available
at some locations in-country. Based on the historical high
rates of P. falciparum,16 RDTs detecting P. falciparum–
specific histidine-rich protein 2 (HRP2) were deployed; thus,
non-falciparum infections would be undetected by the pri-
mary diagnostic test being used in the majority of Haitian
health facilities. Before the earthquake, national malaria prev-
alence was considered low, though highly focal,20,21 but there
were concerns about underreporting due to a lack of access to
diagnosis and a weak surveillance system.21–23
Recent efforts have improved national reporting and access
to malaria diagnosis by RDTs. The Grand’Anse department in
southwestern Haiti has experienced one-third to half of all the
nationally reportedP. falciparummalaria cases in recent years
(source: National Malaria Control Program, PNCM). A case–
control study that was conducted as part of operational re-
search efforts to identify risk factors for P. falciparum offered
an opportunity to test for the presence of non-falciparum
malaria species.24 Post hoc laboratory quantification of HRP2
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and pan-Plasmodium aldolase (pAldolase) antigens allowed
for selection of a subset of samples with possible P. malariae
infection for species-specific testing of parasite nucleic acids.
Weaimed to determine the presenceor absenceofP.malariae
infection in the selected subset of samples collected in
Grand’Anse.
METHODS
Study population. A case–control study was performed in
Grand’Anse, southwestern Haiti, as previously described24
(Figure 1). In short, individuals attending one of four health
facilities between April and July 2018 with suspected malaria
(i.e., self-reported history of, or current, febrile illness,
assessed by the attending healthcare provider) were invited
to participate. The exclusion criteria were younger than
6 months, any severe disease, taking an antimalarial drug in
the 14 days before visiting the health facility, and residence
outside the commune of the recruiting health facility. Partici-
pants with a positive RDT result (SD Bioline Malaria Antigen
P.f., 05FK50, StandardDiagnostics; or First ResponseMalaria
HRP2Antigendetection card test, I13FRC30,PremierMedical
Corporation) were selected as cases and RDT-negative par-
ticipants as controls. Finger-prick blood samples were col-
lected onWhatman 903 cards and stored as dried blood spots
(DBSs) at 4C until processing at the National Laboratory of
Public Health (Laboratoire National de Santé Publique, LNSP)
in Port-au-Prince.
Basic demographic information, contact details, and ap-
proximate home location were collected at the health facility
by the study team to enable a follow-up visit to the household.
During the follow-up visit, a questionnaire was used to collect
information on demographic and behavioral characteristics.
All individuals with a positive RDT result received the national
first-line malaria treatment during their consultation at the
health facility.
Antigenemia and IgG data collection using a multiplex
bead assay. A MBA was performed to collect HRP2 and
pAldolase antigenemia and IgG data to Plasmodium malariae
19-kDa fragment of merozoite surface protein 1 (PmMSP-119)
FIGURE 1. Health facilities included in western Grand’Anse and household locations of study participants according to the selection criteria for
molecular analysis. The inset in the top right showsHaiti (light gray) andneighboringDominicanRepublic (dark gray) aswell as the studyarea (green)
in thewestern part of theGrand’Anse department. Participants from the case–control study24were selected formolecular analysis according to the
following criteria: Selection 1: pAldolase-positive and PmMSP-119–seropositive participants; Selection 2: PmMSP-119–seropositive and PfMSP-
119–seronegative children younger than 15 years. The arrow points at the household location of the 6-month-old infant who tested positive for
Plasmodium malariae by photo-induced electron transfer PCR (PET-PCR). PmMSP-119: Plasmodium malariae 19-kDa fragment of merozoite
surface protein 1; pAldolase: pan-Plasmodium aldolase; PfMSP-119: Plasmodium falciparum 19-kDa fragment of merozoite surface protein 1.
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and Plasmodium falciparum 19-kDa fragment of merozoite
surface protein 1 (PfMSP-119) for all study participants (i.e.,
both cases and controls) using theMAGPIX platform (Millipore
Sigma). Unique bead regions (MagPlex®, Luminex Corp) were
coatedby theEDC/Sulfo-NHS intermediate reactionwith anti-
HRP2 (20 μg per 12.5 × 106 beads mouse IgG anti-PfHRP2
IgG, Abcam) or anti-pAldolase (12.5 μg per 12.5 × 106 beads
rabbit IgG anti-pAldolase IgG, Abcam).13 Biotinylated de-
tection antibodies (mouse IgG anti-HRP2, Abcam, and rabbit
anti-aldolase, Abcam) were prepared at a final concentration
of 1 mg/mL using the EZ-Link Micro Sulfo-NHS-Biotinylation
Kit (ThermoFisher Scientific). Beads and detection antibodies
were transported to LNSP and stored at 4C.
At LNSP, an MBA was used to collect antigenemia data, as
previously described.25 Dried blood spots were punched
(6 mm discs) and eluted overnight in buffer B (PBS pH 7.2,
0.5% polyvinyl alcohol, Sigma; 0.5% polyvinylpyrrolidine,
Sigma; 0.1% casein, ThermoFisher; 0.5% BSA, Sigma; 0.3%
Tween 20; 0.1% sodium azide; and 0.1% E. coli extract) to a
final sample dilution of 1:20 whole blood. Bead mix was pre-
pared in buffer A (PBSpH7.2, 0.1%Tween 20, 0.5%BSA, and
0.1% sodium azide), beads added to plates (BioPlex Pro,
BioRad) aiming for 800 beads/region/well, and washed ×2
with 100 μL wash buffer (PBS pH 7.2, 0.15% Tween 20). The
samples (50 μL) were incubated with the beads for 90minutes
(all incubation steps were carried out under gentle shaking at
ambient temperature) and subsequently washed ×3. Beads
were incubated with detection antibodies (50 μL; 1:500 anti-
HRP2 and 1:1,000 anti-aldolase in buffer A) for 45 minutes.
The plates were washed ×3 and then incubated with
streptavidin–phycoerythrin (strep-PE; 1:200 of 1 mg/mL,
Invitrogen) for 30 minutes. The plates were washed ×3 and
incubated with a final 30-minute wash step with buffer A. The
plates were then washed ×1, resuspended in 100 μL PBS,
shaken briefly, and read on a MAGPIX instrument (Millipore
Sigma), generating median fluorescence intensity (MFI) with a
target of 50 beads/region/well. Median fluorescence intensity
values were corrected for responses of a blank well (contain-
ing buffer B), providing an MFI-bg signal for analyses. The
threshold of positivitywas set at themean+3SDof theMFI-bg
signal of a panel of known negative DBS samples from U.S.
residents without history of travel in the last 6 months.25 Data
were successfully collected for 1,081 participants for PfHRP2
(98%) and 1,059 for pAldolase (96%). Data were excluded for




27 was also collected
with the MBA platform, using a previously described pro-
tocol28with beadpreparation, wash, and incubationmethods,
as described previously. Proteins were covalently coupled to
beads at 20 μg per 12.5 × 106 beads. Dried blood spots were
punched (3-mm disc) and eluted in buffer B at 1:100 approx-
imate serum concentration. Bead mixture was prepared,
added to plates aiming for 600 beads/region/well, and
washed ×2. Sample (50 μL) and anti-IgG (50 μL; 1:500 anti-
human IgG, Southern Biotech; 1:625 anti-human IgG4,
Southern Biotech; 1:200 strep-PE in buffer A) were incubated
simultaneously overnight, and the plates were read the next
day after washing ×3 and resuspending in PBS. Median fluo-
rescence intensity was corrected for buffer B responses
(providing an MFI-bg assay signal) and log10-transformed. A
two-Gaussian mixture model of log-transformed data was
used to determine the threshold for seropositivity, set at the
mean +3 SD of the lower distribution. Sufficient bead counts
were available for 1,071 participants for PfMSP-119 and 1,070
for PmMSP-119 (97%).
Plasmodium species specification by photo-induced
electron transfer PCR (PET-PCR). Samples for species
specification by PCR were selected according to two sets of
criteria using Plasmodium antigenemia and IgG results
(Figure 2). Driedbloodspots fromselectedparticipants (n=52)
were storedat−20Cuntil shipment at ambient temperature to
the CDC in Atlanta, GA, where they were stored at −20C until
processing.
At the CDC, a PET-PCR assay was performed, as previously
described.29 DNA was extracted from DBSs using the Qiagen
Mini Kit (Qiagen). PCRs for Plasmodium genus, P. falciparum,
andP.malariaewas performed in 20 μL reactions containing ×2
FIGURE 2. Flowchart of criteria to select study participants for
molecular analysis and Plasmodium species specification results.
Rapid diagnostic tests (RDT; First Response PfHRP2 or SD-Bioline
PfHRP2)were performedat the health facilitywhere studyparticipants
sought care for current fever or a history of fever. Serological and
antigenemia datawere collected using the collecteddriedblood spots
(DBSs) at the National Laboratory of Public Health in Port-au-Prince.
Dried blood spots from selected participants were processed for
Plasmodium species specification using photo-induced electron
transfer PCR (PET-PCR) at the Centers of Disease Control and Pre-
vention in Atlanta, GA. PmMSP-119 = Plasmodium malariae 19-kDa
fragment of merozoite surface protein 1; pAldolase = pan-Plasmo-
dium aldolase; PfMSP-119 =Plasmodium falciparum 19-kDa fragment
of merozoite surface protein 1; HRP2 = histidine-rich protein 2; Pf =
Plasmodium falciparum; Pm = Plasmodium malariae; RDT = rapid di-
agnostic test; + = (sero)positive; - = (sero)negative.
PLASMODIUM MALARIAE IN AN INFANT IN HAITI 3
TaqMan Environmental buffer 2.0 (Applied Biosystems). For the
genus reaction, 0.5 μL of both forward and reverse (which was
labeled with FAM dye) primers at 250 nM were included in
each reaction. For the P. falciparum primers, 0.5 μL forward
primer at 250 nMand0.25μL reverse primer at 125 nM (which
was labeled with HEX dye) were included. For the P.malariae
primers, 0.5 μL of both forward and reverse (which was la-
beledwith FAMdye) primers at 250 nMwere included in each
reaction and the sequences were forward (59-AAGGCAG-
TAACACCAGCAGTA-39) and reverse (59-agg cgc ata gcg
cct ggTCCCATGAAGTTATATTCCCGCTC-39) primers. PCR
occurred with the following cycling parameters: initial hot-
start at 95C for 15 minutes, followed by 45 cycles of de-
naturation at 95C for 20 seconds, annealing at 63C for 40
seconds, and final elongation at 72C for 30 seconds. The
cycle threshold (CT) values were recorded at the end of the
annealing step. All assays were performed using an Agilent
M ×3005pro qPCR system (Agilent Technologies). Positivity
of DNA amplificationwas set at CT < 40.0. The sensitivity and
specificity of thePET-PCRassay comparedwith nestedPCR
is 92% and 100%, respectively, with an estimated lower limit
of detection of two parasites/μL blood.29
Ethical approval. The study protocol was approved by
the National Bioethics Committee of the Haitian Ministry of
Public Health and Population (1718-20), Tulane University
(2017-366), and the London School of Hygiene and Tropical
Medicine (14556). The study protocol and institutional ethical
determinationswere reviewed and approvedby theU.S. CDC,
Office of the Associate Director of Science at the Center for
Global Health, and CDC investigators were determined not to
be engaged in human subject research.
Consent fromall participantswas recordedelectronically on
tablets during recruitment at health facilities and confirmed at
follow-up interview. Consent for individuals younger than 18
years was given by a parent or guardian. Mature minors (aged
16–17 years and pregnant, a parent, or head of household)
were able to provide consent directly.
RESULTS
Plasmodium antigenemia and IgG results from partici-
pants in the case–control study. Using an MBA, Plasmo-
dium antigenemia and IgG data were successfully collected
for 1,048 case–control study participants (95%). Data were
excluded if insufficient bead counts were available for any of
the targets (i.e., < 20 beads/well). In total, 841 participants were
negative for HRP2 and pAldolase (HRP2−/pAldolase−); 116
were positive for HRP2 and pAldolase (HRP2+/pAldolase+); 90
were HRP2+/pAldolase−; and one was HRP2−/pAldolase+. In
addition, high IgG levels to PmMSP-119 were seen in the study
population (Figure 3). Age-specificPmMSP-119 seroprevalence
was 0- to 5-year olds: 7% (20/277), 6- to 10-year olds: 9% (15/
163), 11- to 20-year olds: 18% (35/195), 21- to 40-year olds:
28% (71/253), and > 40-year olds: 38% (61/160).
Selection criteria for molecular analysis. Selection 1
consisted of pAldolase + participants, seropositive to PmMSP-
119 (n = 43; Figure 2); pAldolase antigenemia would indicate
current or recent exposure to Plasmodium, whereas PmMSP-
119seropositivity suggestsexposure toP.malariae. Thus, these
might represent single species infection with P. malariae (if no
HRP2 is detected) but might also be mixed P. falciparum/
P. malariae infections or single P. falciparum infections as 98%
were HRP2+ (42/43) and 95%were seropositive to PfMSP-119
(41/43; Figure 3).
Selection 2 comprised children ( aged < 15 years) sero-
positive to PmMSP-119 and seronegative to PfMSP-119 (n = 9;
Figure 2), removing the possibility of PmMSP-119 seroposi-
tivity due to cross-reactivity to PfMSP-119. This selection was
FIGURE 3. IgG responses to PfMSP-119 and PmMSP-119 in all participants in the case–control study in Grand’Anse, Haiti, and according to the
selection criteria for Plasmodium species specification using nucleic testing. Box plots and individual IgG results (jittered dots) are shown. Dashed
horizontal lines represent the threshold for seropositivity. PmMSP-119 = Plasmodium malariae 19-kDa fragment of merozoite surface protein 1;
pAldolase = pan-Plasmodium aldolase; PfMSP-119 = Plasmodium falciparum 19-kDa fragment of merozoite surface protein 1.
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focused on children as in adults, seropositivity to PmMSP-119
might indicate a historical infection, whereas in children, it is
more likely to be related to a recent or current infection. Of
these nine samples, only one was antigen positive: for HRP2.
As no further Plasmodium antigenemia was detected in this
group, the likelihood of detecting a P. malariae infection was
low but still possible as a chronic low-density P. malariae in-
fection, which remained undiagnosed and untreated because
of lack of P. falciparum exposure (i.e., PfMSP-119 seronega-
tive). Alternatively, these could represent a mixed P. falcipa-
rum/P. malariae infection below the lower limit of detection for
pAldolase and/or HRP2 for which seroconversion to PfMSP-
119 has not taken place (yet). Last, these could represent a
singleP. falciparum infection (formost, below the lower limit of
detection of HRP2) for which seroconversion to PfMSP-119
has not taken place (yet).
Species-specific PCR results in selected participants.
Photo-inducedelectron transferPCRconfirmedoneP.malariae
infection (Figure 2). The parasite density of this infection was
approximately 100 parasites/μL of blood. This was the HRP2−/
pAldolase+ sample with PmMSP-119 antibodies that led to the
search for P. malariae in this population. The P. malariae PET-
PCR–positive sample was from a 6-month-old boy who was
enrolled at the health facility in Les Irois in the southwestern part
ofGrand’Anse (Figure1). The infant’scaregiver reportedbednet
use the previous night. No recent travel was reported for the
infant, and no other household members reported fever in the
2 weeks before the interview.
Plasmodium falciparum PET-PCR results confirmed HRP2
RDT results, except for two RDT+/PfPCR− samples in the first
selection group (Figure 2). Multiplex bead assay results con-
firmed the presence of HRP2 in these two samples; thus, they
could represent recently cleared P. falciparum infections with
residual HRP2 circulating. An overview of Plasmodium sero-
logical antigen and PET-PCR positivity results is shown in
Supplemental Table 1.
DISCUSSION
Here, we report the retrospective detection of a P. malariae
infection in an infant who participated in a case–control study
in Grand’Anse, Haiti, in 2018.24 In-country, post hoc Plas-
modium antigenemia and IgG data collection triggered our
search for P. malariae in this population.
The confirmedP.malariae infection in this study occurred in
an infant with a history of fever, seeking care at a local health
facility. As the infant tested negative using a P. falciparum–
specific RDT (i.e., HRP2-based), he would have remained
undiagnosed and untreated for malaria. Plasmodiummalariae
infections can lead to hospitalization and have had fatal out-
comes even inwell-resourced settings.1 The fact that no travel
history was reported suggests that the infection was locally
acquired and thus that P. malariae is circulating in this part of
Haiti. However, the possibility of congenital malaria could not
be excluded as we did not have a sample available from the
infant’s mother. It may be possible that the infant’s PmMSP-
119–seropositive status was due to maternally derived IgG.
Nearly one in five participants in the overall case–control study
was seropositive to PmMSP-119. The health facility that the
infant attended was located in Les Irois, in the southwestern
part of Grand’Anse, which was identified as a focus of
P. falciparum transmission by Ashton et al.24
Data collections in the Artibonite department in 2017 also
found evidence of P. malariae infections, though rare (M.A.
Chang, personal communication). Before this report, themost
recent published evidence suggesting the presence of P.
malariae in Haiti was identification of P. malariae infections
in Haitian refugees arriving in Jamaica in 2004.17 The current
surveillance system in Haiti does not support reporting by
Plasmodium species. Historical reports from Haiti showed
that during localized outbreaks in mountainous areas in
1966, about 15% of the malaria infections were due to
P. malariae, although nationally, they made up 3%.15 Overall, in
1964–1965, the monthly incidence of P. malariae was found to
roughly parallel P. falciparum incidence in nationwide surveys in
Haiti.15
Plasmodium malariae parasites are believed to be sensitive
to chloroquine treatment, the national first-line malaria treat-
ment in Haiti, although data are limited.1 When P. malariae
presents as a mixed infection with P. falciparum, treatment
could still occur in Haiti, unless it is a low-densityP. falciparum
infection below the limit of detection of RDTs. However, in the
case–control study, 13% of participants seropositive to
PmMSP-119 were seronegative to PfMSP-119 (27/202), and
therefore, their infections may have escaped detection, and
they might not have received antimalarial treatment during
their infection.Moreover,P.malariae andmixedP. falciparum/
P. malariae infections are frequently of low density and/or
asymptomatic; thus, they will likely be missed by RDTs or
microscopy.5 In the case described here, the infection ap-
pears tobeasingleP.malariae infection, though thepossibility
of a mixed infection with P. falciparum below the lower limit of
detection of the PET-PCR protocol used (< 2 parasites/μL
blood) cannot be excluded. Regardless, the identified
P.malariae infectionwasnot diagnosedby routinepractices at
the health facility because of the lack of appropriate diag-
nostics to detect non-falciparum infections.
In other countries in the Caribbean, P. malariae has caused
outbreaks decades after successful elimination (i.e., Grenada18
andTrinidad19). Theseoutbreakswerehypothesized tobedue to
recrudescent infections.Plasmodiummalariae is known tocause
extendedperiods of latency; one case inGreece had a latency of
more than 40 years (and possibly as long as 70 years).11 In ad-
dition, there is evidence from some settings that P. malariae
transmission remained or increased while P. falciparum
decreased.1,12 Combined, these reports emphasize the impor-
tance of knowing whether P. malariae is still endemic in Haiti.
A MBA was used to screen for Plasmodium antigenemia
and IgG at the Haitian National Laboratory. This enabled us
to select relevant samples with possible P. malariae in-
fection from the case–control study. As antigenemia data
were collected at < 1 USD per sample13 and PmMSP-119
was added to a panel of P. falciparum antigens at limited
additional costs, this was a highly cost-effective method of
selecting possible non-falciparum infections for sub-
sequent confirmation by PCR as compared with testing all
available samples by PCR.
In addition to the inability to exclude congenital malaria or
gather additional information from the P. malariae case’s
family, a further limitation of our study is the fact that the
original study protocol was not designed to determine the
presence of non-falciparummalaria in this setting. A history
of febrile illness was the inclusion criterion for the case–
control study, although P. malariae is often asymptomatic.5
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Future efforts to assess the burden of non-falciparum
malaria in Haiti should therefore (also) focus on asymp-
tomatic populations.
Whether this finding should have policy implications for
Haiti is difficult to conclude based on a single identified
P. malariae case. However, this may have been a locally ac-
quired infection, and there is currently a lack of diagnostic
capacity for non-falciparum infections in routine care. Con-
sidering Haiti’s elimination aims, this preliminary evidence
warrants further exploration of the extent of non-falciparum
transmission, surveillance approaches, and efficacy of first-
line treatment against non-falciparum species present.
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